drugset / Trial / NCT05198349
First in Human Study of M1069 in Advanced Solid Tumors
Phase 1
Terminated
15 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.
Timeline
- Start
- 2022-03-02
- Primary completion
- 2023-05-09
- Completion
- 2023-08-10
Outcome
Outcome not reported
Stopped (Business): “Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M1069 | Unknown | — | Oral |